Factive gemifloxacin mesylate regulatory update

OSCID submitted a complete response to an FDA approvable letter for a 5-day course of Factive to treat

Read the full 184 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE